WO2008062998A1 - Method for purifying hyaluronic acid - Google Patents
Method for purifying hyaluronic acid Download PDFInfo
- Publication number
- WO2008062998A1 WO2008062998A1 PCT/KR2007/005857 KR2007005857W WO2008062998A1 WO 2008062998 A1 WO2008062998 A1 WO 2008062998A1 KR 2007005857 W KR2007005857 W KR 2007005857W WO 2008062998 A1 WO2008062998 A1 WO 2008062998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- precipitate
- charcoal
- organic solvent
- impurities
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 111
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 111
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000012535 impurity Substances 0.000 claims abstract description 37
- 239000003610 charcoal Substances 0.000 claims abstract description 28
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000002244 precipitate Substances 0.000 claims description 27
- 238000000108 ultra-filtration Methods 0.000 claims description 23
- 239000003960 organic solvent Substances 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 18
- 239000003463 adsorbent Substances 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 15
- 239000005909 Kieselgur Substances 0.000 claims description 14
- 229910021645 metal ion Inorganic materials 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 3
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 18
- 108090000623 proteins and genes Proteins 0.000 abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 abstract description 17
- 102000039446 nucleic acids Human genes 0.000 abstract description 17
- 108020004707 nucleic acids Proteins 0.000 abstract description 17
- 239000002158 endotoxin Substances 0.000 abstract description 15
- 244000005700 microbiome Species 0.000 abstract description 7
- 238000000855 fermentation Methods 0.000 abstract description 4
- 230000004151 fermentation Effects 0.000 abstract description 4
- 239000000049 pigment Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000746 purification Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 150000003863 ammonium salts Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- -1 Zinc aluminate Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000011218 seed culture Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002510 pyrogen Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000194048 Streptococcus equi Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 229940070891 pyridium Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Definitions
- the present invention relates to a method for purifying hyaluronic acid in high purity, which comprises ultrafiltering hyaluronic acid-containing culture broth obtained by fermentation of microorganism to remove hyaluronic acid having a low molecular weight and pigments, and adding charcoal and optionally gamma alumina to remove impurities including proteins, nucleic acids, endotoxins, etc.
- the present invention also relates to a method for purifying hyaluronic acid or salts thereof, which comprises the step of removing metal ions.
- Hyaluronic acid is colorless, transparent, highly viscose, and linear polysaccharides having a molecular weight ranging from 50,000 to 10,000,000 Daltons , and has the repeating untis of glucuronic acid and N-acetylglucosamine combined in alternative linkage at (1-3) and (1-4) positions.
- Hyaluronic acid is widely distributed in skin, vitreous body of eye, joint fluid, umbilical cord, rooster comb, etc., or produced by bacteria such as Streptococcus genus, etc.
- Hyaluronic acid having a high molecular weight shows lubrication effect and protection effect against bacterial infection, etc., and so has been widely used as additive in cosmetics, protective agent for ocular tissue during ophthalmic operation, therapeutic agent for degenerative arthritis, etc.
- US 4,517,295 discloses a method for purifying hyaluronic acid by adding trichloroacetic acid to a culture broth of Streptococcus pyogenes to flocculate the cells, filtering the broth through a 0.2 ⁇ m filter to remove the cells, removing the medium- derived contaminants having a low molecular weight by using a membrane having the molecular weight cut off of 30,000 Da, and precipitating hyaluronic acid from the solution by adding an organic solvent.
- the precipitate in order to obtain a highly pure hyaluronic acid, the precipitate is redissolved, and such salts as CETAB (a mixed trimethylammonium bromide), CPC (cetyl pyridium chloride), etc. are used to obtain precipitate. This precipitate is then dissolved, and subjected to a sterilizing filter.
- US 4,782,046 discloses a method wherein 0.01% of anionic surfactant lauryl sulfate is added to a culture broth of Streptococcus equi to separate hyaluronic acid attached to the cell wall, the hyaluronic acid is precipitated by adding nonionic surfactant hexade- cyltrimethyl ammonium bromide, the precipitate was dissolved in 2M calcium chloride (CaCl ) solution, and the cells are centrifuged or filtered to obtain supernatant. Alcohol is added to the supernatant to precipitate and recover hyaluronic acid. A complicated process of dissolving precipitate, adding alcohol to precipitate hyaluronic acid, and recovering the precipitate is further carried out at least three times to purify hyaluronic acid.
- anionic surfactant lauryl sulfate is added to a culture broth of Streptococcus equi to separate hyaluronic acid attached to the cell wall
- US 4,784,990 discloses a method wherein the culture broth of Streptococcus zooepidemicus is diluted 3-4 fold with 3% acetic acid buffer solution, and the medium is filtered by using 05g/L of diatomaceous-earth as a filter-aid to remove the cells. The same amount of isopropanol is added to the supernatant, the resulting precipitate is dissolved, isopropanol is added again, the resulting precipitate is re-dissolved, lg/L of charcoal is added, and the mixture is filtered to remove charcoal. Isopropanol is added again to the filtrate, and the precipitate is washed with isopropanol and dried.
- JP-A-63-012293 provides a method of treating hyaluronic acid-containing solution with macroreticular anionic exchange resin having high divinylbenzene content (Dianion HPA-25, HPA-75, IRA-900, IRA-904) to remove pyrogens and proteins.
- macroreticular anionic exchange resin having high divinylbenzene content (Dianion HPA-25, HPA-75, IRA-900, IRA-904) to remove pyrogens and proteins.
- the culture broth of Streptococcus zooepidemicus is diluted with water, charcoal is added to adsorp impurities, and then removed by filtration.
- the supernatant is passed through a column filled with macroreticular anionic exchange resin, sodium chloride is added in a concentration of IM, an organic solvent such as ethanol, etc. is added, and the resulting precipitate is washed with ethanol, and dried.
- this method uses 25L of expensive anionic exchange resin per 3L of broth
- KR Patent No. 10-0236766 describes a method wherein ethanol is added to the culture broth of hyaluronic acid-producing strain to precipitate hyaluronic acid, the precipitate is washed with 65% ethanol several times, the precipitated is dissolved, and charcoal is added to adsorp impurities and removed by filtration.
- Zinc aluminate powder is added to adsorp impurities, and removed by filtration.
- the resulting solution is passed through a silica gel column, filtered through a 0.2 ⁇ m filter, precipitated by ethanol, and washed with ethanol several times to obtain purified hyaluronic acid.
- KR Patent No. 10-0149793 describes a purification method characterized in that hyaluronic acid-containing solution recovered from the broth is treated with hydrophobic polymer (polyethylene, polypropylene, polystyrene), activated alumina is added to selectively remove impurities and hyaluronic acid having a low molecular weight, an organic solvent is added, and the precipitated hyaluronic acid is dried under vacuum.
- hydrophobic polymer polyethylene, polypropylene, polystyrene
- activated alumina activated alumina is added to selectively remove impurities and hyaluronic acid having a low molecular weight
- an organic solvent is added, and the precipitated hyaluronic acid is dried under vacuum.
- JP 2731545 describes a method wherein the broth is diluted with water, centrifuged to remove the cells, and ultrafiltered to remove the medium. Hyaluronic acid is precipitated by ethanol, and dried under vacuum. The resulting precipitate is dissolved, the hyaluronic acid-containing solution is treated by alumina and silica gel one after the other to remove pyrogens, proteins, nucleic acids, metallic impurities, etc., and an organic solvent is added to precipitate the purified hyaluronic acid.
- JP- A-06- 199656 describes a method wherein the hyaluronic acid-containing solution is passed through a membrane filter charged to pH 6-10 to remove pyrogens, and ethanol is added to precipitate the purified hyaluronic acid.
- the above methods using an adsorbent should include the steps of precipitating by ethanol, washing, drying, and dissolving prior to the adsorbent treatment. Accordingly, the total time to carry out the process becomes longer, with making the process more complicated.
- the present invention is to provide a method for easily purifying hyaluronic acid from a hyaluronic acid-containing culture broth that is obtained by fermentation of microorganism.
- the present invention relates to a method for purifying hyaluronic acid or salts thereof, which comprises the steps of
- step (d) adding an organic solvent to the solution obtained in step (c) to precipitate hyaluronic acid, washing the precipitate with an organic solvent, and drying the precipitate.
- the present invention provides a method for obtaining highly pure hyaluronic acid more conveniently, characterized in that (i) ultrafiltration and (ii) charcoal and optionally gamma alumina treatment are subjected one after the other after removal of the cells.
- the present invention also relates to a method for purifying hyaluronic acid or salts thereof, which comprises the step of removing metal ions.
- the culture broth containing hyaluronic acid in the present invention may be obtained by culturing the hyaluronic acid-producing strains known in the art, for example, strains from Streptococcus genus, preferably Streptococcus equi, Streptococcus zooepidemicus, and Streptococcus pyogen, under a culture condition known for each strain. Specific kinds of strains and culture conditions are known in the art.
- the cells may be removed from the hyaluronic acid-containing broth by any method known in the art, for example, centrifugation, organic acid precipitation, filtration, etc. Filtration may be carried out by using filter press, drum filter, depth filter or membrane filter, and diatomaceous earth or perlite is used as a filter aid. Preferably, depth filter is used with diatomaceous earth as a filter aid.
- Diatomaceous earth is a porous particle having silicone oxide (SiO ) as the main component, and usually used as a filter aid. If the cells are removed from the hyaluronic acid-containing broth by using diatomaceous earth as a filter aid, the diatomaceous earth particles are piled with the cells, and prevent the blockade of the filter membrane, and so the filtration can be facilitated. Also, the cells may be filtered by the porous structure of the diatomaceous earth, whereby the removal efficiency of the cells can be improved. As the amount of diatomaceous earth used decreases, the cells block the pores of the filter and make the filtration time longer. On the other hand, as the amount of diatomaceous earth used increases, broader filtration area is needed. Generally, the amount of diatomaceous earth used for the removal of cells preferably is in the range of 05 to 5%, and the concentration of hyaluronic acid preferably in the range of 05 to 20g/L.
- silicone oxide SiO
- the present invention has the technical feature that ultrafiltration is directly applied without the time-consuming and complicated organic solvent treatment.
- the ultrafiltration herein means that the solution is passed through a membrane having a constant pore size. The substances having a lower molecular weight pass through the pore, and those having a higher molecular weight remain on the membrane. Under the situation, water is continuously supplied to remove the substances having a lower molecular weight.
- the hyaluronic acid having a low molecular weight and the impurities derived from the broth may be removed.
- the molecular weight cut off of the ultrafiltration filter that can be preferably used in the present invention ranges from 5,000 to 300,000Da, more preferably from 10,000 to 100,000Da.
- the use of filter whose cut off is more than 300,000Da allows hyaluronic acid to get through the filter to make the yield low.
- the use of filter whose cut off is less than 5,000Da results in slow filtration and insufficient removal of substances having a high molecular weight, which all lower the removal efficiency of impurities. It is preferable that the ultrafiltration is performed until the conductivity of the hyaluronic acid filtrate reaches 4mS/cm or less.
- charcoal and optionally gamma alumina are added as adsorbent.
- Use of gamma alumina is not indispensable, but it is preferable to add gamma alumina with charcoal (see Example 3).
- Charcoal is carbon-based particles having a high adsorption effect, and shows an excellent ability to remove proteins, nucleic acids, endotoxins, etc. If gamma alumina is further added, the residual proteins that are not removed by the single use of charcoal can be removed effectively. This effect can be confirmed by Example 3.
- the charcoal treatment is carried out under the hyaluronic acid concentration of 05 ⁇ 20g/L, pH of 4.0-8.0 and the temperature of 0-40 0 C.
- the low concentration of hyaluronic acid results in decreased treatment efficiency, and the high concentration thereof results in high viscosity and poor mixing.
- Sodium chloride may be added to the solution, for example, at the concentration of about IM, during the step of adsorbent.
- Sodium chloride may contribute to the adsorption of impurities to the adsorbent, and may change the shape and density of precipitates in the ethanol precipitation step in the desirable manner.
- ethanol is added at a low concentration of sodium chloride, hyaluronic acid precipita tes in the form of fiber, and so the process further needs homogenization process (e.g., cutting process) after drying.
- homogenization process e.g., cutting process
- the present invention purifies hyaluronic acid in the order of removing the cells preferably by diatomaceous earth, ultrafiltrating without the organic solvent precipitation, and adsorbing by adding charcoal preferably with gamma alumina.
- This method can give desired hyaluronic acid in a higher purity than the case of not carrying out the ultrafiltration or adsorption process, or of reversing the order.
- the constitutions according to the present invention i.e., carrying out ultrafiltration and adsorption together and taking the order of ultrafiltration first and adsorption later, exhibit excellent effect in decreasing the amount of impurities such as proteins, endotoxins, nucleic acids, etc. to give hyaluronic acid in high purity.
- the present inventors have confirmed according to the present invention that decrease of metal ion content in the purified hyaluronic acid contributes to the prevention of inflammation reaction, particularly in eyes.
- hyaluronic acid for medical use requires NF (Non-inflammatory activity).
- NF Non-inflammatory activity
- the inventors have found that inflammation reaction may occur although hyaluronic acid is purified to meet the standards of protein, nucleic acid and endotoxin under the European Pharmacopoeia, and confirmed that the cause of inflammation lies in the presence of metal ion.
- Hyaluronic acid is negatively charged very strongly, and so metal cations, especially alkaline earth metal ions, can easily bind thereto. Thus, even the purified hyaluronic acid may have a large amount of metal ions.
- any method known in the art may be used for decreasing the metal ion content in the hyaluronic acid.
- Chelating agent more preferably EDTA, may be used for this purpose.
- This step of removing metal ions may be additionally applied to any method of purifying hyaluronic acid, and preferably, to the purification method according to the present invention.
- the step of removing metal ions may be inserted to any step of the above mentioned purification method, but the present inventors have found that the metallic impurities can be easily removed by adding EDTA to the solution after the charcoal treatment. For example, as confirmed by Comparative Example 5 and Table 4, such metallic impurities as barium, calcium, magnesium, etc.
- EDTA treatment conducted after the charcoal and optionally gamma alumina treatment according to the present invention gives hyaluronic acid which does not induce any inflammation reaction and is safe as a medicine.
- an organic solvent is introduced to the solution for the precipitation of hyaluronic acid, whereby the purified hyaluronic acid can be recovered.
- the organic solvent any conventional organic solvent such as ethanol, methanol, acetone, isopropyl alcohol, etc., preferably ethanol, may be used.
- an organic solvent washing process may be additionally carried out for further removing impurities and making the drying process easy.
- Hyaluronic acid precipitated by an organic solvent is dried according to a conventional drying process known in the art, for example, nitrogen or air purging, freeze drying, vacuum drying, etc., to give the purified hyaluronic acid as white solid.
- the present inventors determined whether the finally obtained hyaluronic acid solid meets the standards of use as a medicine, according to the following method.
- the hyaluronic acid sodium salt is dissolved to the concentration of lmg/ mi , and tested by using the LAL kit of Charles River Endosafe.
- the endotoxin content standard under the European Pharmacopoeia is 0.05 IU/mg or less.
- the protein is dissolved to the concentration of lOmg/ m# , and quantified by Lo wry method.
- the protein content standard under the European Pharmacopoeia is 0.1% or less.
- the protein of the sample in the intermediate step of purification is quantified by measuring the absorbance at 280nm.
- nucleic acid O.lOg of hyaluronic acid is dissolved to the final volume of 30.0 m#, and quantified by measuring the absorbance at 260nm.
- the nucleic acid content standard under the European Pharmacopoeia is 05 or less.
- metallic impurities 0.25g of hyaluronic acid is dissolved in 1 mi of nitric acid, heated, diluted to 10.0 m# with purified water, and quantified by the atomic absorption spectrometry II according to the European Pharmacopoeia (see Sodium Hyaluronate Test Method and Bacterial Endotoxins in the European Pharmacopoeia).
- a medium having the final concentrations of 20g/L of glucose, 30g/L of yeast extract, 9g/L of sodium glutamate, 2g/L of sodium chloride, 2g/L of magnesium sulfate, and 2g/L of potassium phosphate dibasic was prepared. Only, glucose and magnesium sulfate were dissolved in another flask, sterilized, cooled, and mixed with the other components.
- Step 1.1 To 50 m# of the medium prepared in Step 1.1 was inoculated 1 mi of Streptococcus zooepidemicus (KCTC 0075BP), and the mixture was incubated for about 24 h in a shaking incubator under the conditions of 35 0 C and lOOrpm.
- KCTC 0075BP Streptococcus zooepidemicus
- Step 1.1 To 950 m# of the medium prepared in Step 1.1 was inoculated 50 m# of the broth of seed culture 1 prepared in Step 1.2, and the mixture was incubated for about 24 h in a shaking incubator under the conditions of 35 0 C and lOOrpm.
- a medium having the final concentrations of 70g/L of glucose, 30g/L of yeast extract, 9g/L of sodium glutamate, 2g/L of sodium chloride, and 2g/L of magnesium sulfate was prepared. Glucose and magnesium sulfate were dissolved in another flask and sterilized. The other components were sterilized in a 15L fermenter, cooled, and mixed with the components in the flask.
- Example 1 To the hyaluronic acid-containing broth prepared in Example 1 was added the same volume of purified water to dilute the solution to have the concentration of hyaluronic acid within the range of 0.1-0.4%. 2% of diatomaceous earth with respect to the diluted solution was added, and the resulting solution was filtered through a depth filter to remove the cells and to obtain the hyaluronic acid-containing supernatant.
- Hyaluronic acid was purified according to the same procedure as Example 2 except that EDTA treatment was not carried out.
- the following Table 4 compares the concentrations of metallic impurities in the purification product obtained with or without the EDTA treatment. The results of Table 4 show that the EDTA treatment is essential for treating metallic impurities.
- the purification method according to the present invention can be broadly used for purifying hyaluronic acid from the hyaluronic acid-containing broth obtained by the culture of microorganism. Also, the present invention makes it possible to omit the complicated organic solvent precipitation step in the purification process, whereby hyaluronic acid having a high purity can be obtained by a simple and economical method. Thus obtained hyaluronic acid has a purity that is appropriate as a medicine.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Water Supply & Treatment (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to a method for purifying hyaluronic acid or salts thereof. Specifically, the present invention relates to a method for purifying hyaluronic acid or salts thereof in high purity, which comprises ultrafiltering hyaluronic acid-containing culture broth obtained by fermentation of microorganism to remove hyaluronic acid having a low molecular weight and pigments, and adding charcoal and optionally gamma alumina to remove impurities including proteins, nucleic acids, endotoxins, etc.
Description
Description METHOD FOR PURIFYING HYALURONIC ACID
[1] [ Technical Field ]
[2] The present invention relates to a method for purifying hyaluronic acid in high purity, which comprises ultrafiltering hyaluronic acid-containing culture broth obtained by fermentation of microorganism to remove hyaluronic acid having a low molecular weight and pigments, and adding charcoal and optionally gamma alumina to remove impurities including proteins, nucleic acids, endotoxins, etc. The present invention also relates to a method for purifying hyaluronic acid or salts thereof, which comprises the step of removing metal ions.
[3]
[4] L Background Art J
[5] Hyaluronic acid is colorless, transparent, highly viscose, and linear polysaccharides having a molecular weight ranging from 50,000 to 10,000,000 Daltons , and has the repeating untis of glucuronic acid and N-acetylglucosamine combined in alternative linkage at (1-3) and (1-4) positions. Hyaluronic acid is widely distributed in skin, vitreous body of eye, joint fluid, umbilical cord, rooster comb, etc., or produced by bacteria such as Streptococcus genus, etc.
[6] Hyaluronic acid having a high molecular weight shows lubrication effect and protection effect against bacterial infection, etc., and so has been widely used as additive in cosmetics, protective agent for ocular tissue during ophthalmic operation, therapeutic agent for degenerative arthritis, etc.
[7] There are two methods for obtaining hyaluronic acid: one is to extract hyaluronic acid from the above mentioned tissues of a living body, and the other is to ferment microorganism and recover hyaluronic acid as a fermentation product.
[8] The method for purifying hyaluronic acid from animal tissues such as rooster comb, umbilical cord, etc. (US 4,141,973) is not appropriate for mass production due to high cost because it requires complicated purification steps to remove macromolecular impurities such as chondroitin sulfate, glucosaminoglycan, etc. Also, in this method, it is probable that the pathogenic materials derived from animals are retained in the product.
[9] On the other hand, the production of hyaluronic acid by using a microorganism takes a relatively low production cost, and the hyaluronic acid having a high molecular weight can be obtained in high yield by a simple purification process. It is also
reported that the possibility of retainment of pathogenic materials derived from animals is low in this method.
[10] Highly pure hyaluronic acid is required for hyaluronic acid to be used for commercial use, in particular, for medical use. The following methods are known in the art for the purification of hyaluronic acid produced by microorganisms.
[11] US 4,517,295 discloses a method for purifying hyaluronic acid by adding trichloroacetic acid to a culture broth of Streptococcus pyogenes to flocculate the cells, filtering the broth through a 0.2 μm filter to remove the cells, removing the medium- derived contaminants having a low molecular weight by using a membrane having the molecular weight cut off of 30,000 Da, and precipitating hyaluronic acid from the solution by adding an organic solvent. In this method, in order to obtain a highly pure hyaluronic acid, the precipitate is redissolved, and such salts as CETAB (a mixed trimethylammonium bromide), CPC (cetyl pyridium chloride), etc. are used to obtain precipitate. This precipitate is then dissolved, and subjected to a sterilizing filter. The resulting hyaluronic acid shows a protein content of 0.3-0.03% and a nucleic acid content of A =0.314, which does not meet the protein content standard of 0.1 % or
260 less under the European Pharmacopoeia.
[12] US 4,782,046 discloses a method wherein 0.01% of anionic surfactant lauryl sulfate is added to a culture broth of Streptococcus equi to separate hyaluronic acid attached to the cell wall, the hyaluronic acid is precipitated by adding nonionic surfactant hexade- cyltrimethyl ammonium bromide, the precipitate was dissolved in 2M calcium chloride (CaCl ) solution, and the cells are centrifuged or filtered to obtain supernatant. Alcohol is added to the supernatant to precipitate and recover hyaluronic acid. A complicated process of dissolving precipitate, adding alcohol to precipitate hyaluronic acid, and recovering the precipitate is further carried out at least three times to purify hyaluronic acid.
[13] US 4,784,990 discloses a method wherein the culture broth of Streptococcus zooepidemicus is diluted 3-4 fold with 3% acetic acid buffer solution, and the medium is filtered by using 05g/L of diatomaceous-earth as a filter-aid to remove the cells. The same amount of isopropanol is added to the supernatant, the resulting precipitate is dissolved, isopropanol is added again, the resulting precipitate is re-dissolved, lg/L of charcoal is added, and the mixture is filtered to remove charcoal. Isopropanol is added again to the filtrate, and the precipitate is washed with isopropanol and dried. In order to use the hyaluronic acid as a medicine, complicated purification steps should be further carried out, which comprises dissolving said precipitate, adding CPC (Cetyl
pyridium chloride), dissolving the resulting precipitate, adding isopropanol again, dissolving the resulting precipitate, adding CPC, dissolving the resulting precipitate, passing the resulting solution through a magnesium silicate column and a 0.2 μm filter, adding isopropanol, and finally washing the resulting precipitate with ethanol.
[14] The above-mentioned methods commonly use quarternary ammonium salt to remove impurities. However, the use of quarternary ammonium salt requires a long time in re- dissolving the precipitate, during which a large amount of waste water containing the surfactant quarternary ammonium salt is generated. In particular, it is highly probable that the quarternary ammonium salt is retained in the final product.
[15] Thus, in order to avoid such demerit, the following method using ion exchange resin, without using quarternary ammonium salt, has been developed.
[16] JP-A-63-012293 provides a method of treating hyaluronic acid-containing solution with macroreticular anionic exchange resin having high divinylbenzene content (Dianion HPA-25, HPA-75, IRA-900, IRA-904) to remove pyrogens and proteins. Specifically, the culture broth of Streptococcus zooepidemicus is diluted with water, charcoal is added to adsorp impurities, and then removed by filtration. The supernatant is passed through a column filled with macroreticular anionic exchange resin, sodium chloride is added in a concentration of IM, an organic solvent such as ethanol, etc. is added, and the resulting precipitate is washed with ethanol, and dried. However, this method uses 25L of expensive anionic exchange resin per 3L of broth, and so is not economical enough to be applied to commercial production.
[17] Accordingly, the following method using a relatively cheap adsorbent for the removal of impurities has been developed.
[18] KR Patent No. 10-0236766 describes a method wherein ethanol is added to the culture broth of hyaluronic acid-producing strain to precipitate hyaluronic acid, the precipitate is washed with 65% ethanol several times, the precipitated is dissolved, and charcoal is added to adsorp impurities and removed by filtration. Zinc aluminate powder is added to adsorp impurities, and removed by filtration. The resulting solution is passed through a silica gel column, filtered through a 0.2 μm filter, precipitated by ethanol, and washed with ethanol several times to obtain purified hyaluronic acid.
[19] KR Patent No. 10-0149793 describes a purification method characterized in that hyaluronic acid-containing solution recovered from the broth is treated with hydrophobic polymer (polyethylene, polypropylene, polystyrene), activated alumina is added to selectively remove impurities and hyaluronic acid having a low molecular weight, an organic solvent is added, and the precipitated hyaluronic acid is dried under
vacuum.
[20] Further, a method of using ultrafiltration and filtration through an electrically charged filter together with the adsorbent treatment has been developed to increase the efficiency of removing impurities.
[21] JP 2731545 describes a method wherein the broth is diluted with water, centrifuged to remove the cells, and ultrafiltered to remove the medium. Hyaluronic acid is precipitated by ethanol, and dried under vacuum. The resulting precipitate is dissolved, the hyaluronic acid-containing solution is treated by alumina and silica gel one after the other to remove pyrogens, proteins, nucleic acids, metallic impurities, etc., and an organic solvent is added to precipitate the purified hyaluronic acid.
[22] JP- A-06- 199656 describes a method wherein the hyaluronic acid-containing solution is passed through a membrane filter charged to pH 6-10 to remove pyrogens, and ethanol is added to precipitate the purified hyaluronic acid.
[23] However, the above methods using an adsorbent should include the steps of precipitating by ethanol, washing, drying, and dissolving prior to the adsorbent treatment. Accordingly, the total time to carry out the process becomes longer, with making the process more complicated.
[24] The methods as explained above are not appropriate for the mass production due to their complexity, or do not thoroughly remove such impurities as proteins, pyrogens, nucleic acids, metals, etc. When a quarternary ammonium salt such as CPC, etc. is used, the salt may be retained in the purified hyaluronic acid. The use of adsorbent also requires ethanol precipitation and dissolution process as pretreatment. Therefore, a simple method for purifying hyaluronic acid in high purity has been required.
[25]
[26] [ Disclosure ]
[27] [ Technical Problem ]
[28] The present inventors have extensively studied to develop a simple method that can be easily applied to mass production as well as can produce highly pure hyaluronic acid by effectively removing such impurities as proteins, nucleic acids, endotoxins, metal ions, etc. As a result, the inventors found that such purpose can be achieved by a method as explained below, and so completed the present invention.
[29] Thus, the present invention is to provide a method for easily purifying hyaluronic acid from a hyaluronic acid-containing culture broth that is obtained by fermentation of microorganism.
[30]
[31] [ Technical Solution ]
[32] The present invention relates to a method for purifying hyaluronic acid or salts thereof, which comprises the steps of
[33] (a) removing cells from a hyaluronic acid-containing broth,
[34] (b) ultrafiltering the cell-free broth,
[35] (c) adding charcoal and optionally gamma alumina to the solution obtained in step
(b) to adsorb impurities, and removing the adsorbent, and
[36] (d) adding an organic solvent to the solution obtained in step (c) to precipitate hyaluronic acid, washing the precipitate with an organic solvent, and drying the precipitate.
[37] Specifically, the present invention provides a method for obtaining highly pure hyaluronic acid more conveniently, characterized in that (i) ultrafiltration and (ii) charcoal and optionally gamma alumina treatment are subjected one after the other after removal of the cells.
[38] The present invention also relates to a method for purifying hyaluronic acid or salts thereof, which comprises the step of removing metal ions.
[39]
[40] [ Best Mode ]
[41] The culture broth containing hyaluronic acid in the present invention may be obtained by culturing the hyaluronic acid-producing strains known in the art, for example, strains from Streptococcus genus, preferably Streptococcus equi, Streptococcus zooepidemicus, and Streptococcus pyogen, under a culture condition known for each strain. Specific kinds of strains and culture conditions are known in the art.
[42] The cells may be removed from the hyaluronic acid-containing broth by any method known in the art, for example, centrifugation, organic acid precipitation, filtration, etc. Filtration may be carried out by using filter press, drum filter, depth filter or membrane filter, and diatomaceous earth or perlite is used as a filter aid. Preferably, depth filter is used with diatomaceous earth as a filter aid.
[43] Diatomaceous earth is a porous particle having silicone oxide (SiO ) as the main component, and usually used as a filter aid. If the cells are removed from the hyaluronic acid-containing broth by using diatomaceous earth as a filter aid, the diatomaceous earth particles are piled with the cells, and prevent the blockade of the filter membrane, and so the filtration can be facilitated. Also, the cells may be filtered by the porous structure of the diatomaceous earth, whereby the removal efficiency of
the cells can be improved. As the amount of diatomaceous earth used decreases, the cells block the pores of the filter and make the filtration time longer. On the other hand, as the amount of diatomaceous earth used increases, broader filtration area is needed. Generally, the amount of diatomaceous earth used for the removal of cells preferably is in the range of 05 to 5%, and the concentration of hyaluronic acid preferably in the range of 05 to 20g/L.
[44] In the prior arts, organic solvent treatment is conventionally carried out after removal of the cells. However, the present invention has the technical feature that ultrafiltration is directly applied without the time-consuming and complicated organic solvent treatment. The ultrafiltration herein means that the solution is passed through a membrane having a constant pore size. The substances having a lower molecular weight pass through the pore, and those having a higher molecular weight remain on the membrane. Under the situation, water is continuously supplied to remove the substances having a lower molecular weight. Thus, if ultrafiltration is carried out directly after the removal of the cells, the hyaluronic acid having a low molecular weight and the impurities derived from the broth may be removed. The molecular weight cut off of the ultrafiltration filter that can be preferably used in the present invention ranges from 5,000 to 300,000Da, more preferably from 10,000 to 100,000Da. The use of filter whose cut off is more than 300,000Da allows hyaluronic acid to get through the filter to make the yield low. In contrast, the use of filter whose cut off is less than 5,000Da results in slow filtration and insufficient removal of substances having a high molecular weight, which all lower the removal efficiency of impurities. It is preferable that the ultrafiltration is performed until the conductivity of the hyaluronic acid filtrate reaches 4mS/cm or less.
[45] After the ultrafiltration process, charcoal and optionally gamma alumina are added as adsorbent. Use of gamma alumina is not indispensable, but it is preferable to add gamma alumina with charcoal (see Example 3). Charcoal is carbon-based particles having a high adsorption effect, and shows an excellent ability to remove proteins, nucleic acids, endotoxins, etc. If gamma alumina is further added, the residual proteins that are not removed by the single use of charcoal can be removed effectively. This effect can be confirmed by Example 3. That is, even though charcoal is more adsorptive than gamma alumina, when gamma alumina is used with charcoal, the ad- sorptivity of charcoal jumps up (see Table 3). Charcoal is used in an amount of 05-5%, and alumina is preferably used in an amount of 0-3%. Increased amount of adsorbent is beneficial for the effective removal of impurities. However, excess use of
adsorbent requires more cost, and also decreases the yield due to the adsorption of hyaluronic acid to the adsorbent. If the amount of adsorbent is not sufficient, impurities cannot be effectively removed. It is preferable that the charcoal treatment is carried out under the hyaluronic acid concentration of 05~20g/L, pH of 4.0-8.0 and the temperature of 0-40 0C. The low concentration of hyaluronic acid results in decreased treatment efficiency, and the high concentration thereof results in high viscosity and poor mixing.
[46] Sodium chloride may be added to the solution, for example, at the concentration of about IM, during the step of adsorbent. Sodium chloride may contribute to the adsorption of impurities to the adsorbent, and may change the shape and density of precipitates in the ethanol precipitation step in the desirable manner. Specifically, if ethanol is added at a low concentration of sodium chloride, hyaluronic acid precipita tes in the form of fiber, and so the process further needs homogenization process (e.g., cutting process) after drying. Reversely, if ethanol is added at a high concentration of sodium chloride, hyaluronic acid precipitates in the form of particle, resulting in the homogeneous precipitate having a reduced volume.
[47] As explained above, the present invention purifies hyaluronic acid in the order of removing the cells preferably by diatomaceous earth, ultrafiltrating without the organic solvent precipitation, and adsorbing by adding charcoal preferably with gamma alumina. This method can give desired hyaluronic acid in a higher purity than the case of not carrying out the ultrafiltration or adsorption process, or of reversing the order. For example, as can be seen from Comparative Examples 1, 2, 3, 4, and Tables 1 and 2, the constitutions according to the present invention, i.e., carrying out ultrafiltration and adsorption together and taking the order of ultrafiltration first and adsorption later, exhibit excellent effect in decreasing the amount of impurities such as proteins, endotoxins, nucleic acids, etc. to give hyaluronic acid in high purity.
[48] Also, the present inventors have confirmed according to the present invention that decrease of metal ion content in the purified hyaluronic acid contributes to the prevention of inflammation reaction, particularly in eyes. Generally, hyaluronic acid for medical use requires NF (Non-inflammatory activity). However, the inventors have found that inflammation reaction may occur although hyaluronic acid is purified to meet the standards of protein, nucleic acid and endotoxin under the European Pharmacopoeia, and confirmed that the cause of inflammation lies in the presence of metal ion. Hyaluronic acid is negatively charged very strongly, and so metal cations, especially alkaline earth metal ions, can easily bind thereto. Thus, even the purified
hyaluronic acid may have a large amount of metal ions.
[49] Any method known in the art may be used for decreasing the metal ion content in the hyaluronic acid. Chelating agent, more preferably EDTA, may be used for this purpose. This step of removing metal ions may be additionally applied to any method of purifying hyaluronic acid, and preferably, to the purification method according to the present invention. The step of removing metal ions may be inserted to any step of the above mentioned purification method, but the present inventors have found that the metallic impurities can be easily removed by adding EDTA to the solution after the charcoal treatment. For example, as confirmed by Comparative Example 5 and Table 4, such metallic impurities as barium, calcium, magnesium, etc. are detected in considerable amounts when EDTA is not used, but they are simply and effectively removed when EDTA is used. It is preferable to adjust the concentration of EDTA to 0.01-1OmM. Thus, the present inventors confirmed that EDTA treatment conducted after the charcoal and optionally gamma alumina treatment according to the present invention gives hyaluronic acid which does not induce any inflammation reaction and is safe as a medicine.
[50] After the charcoal treatment, an organic solvent is introduced to the solution for the precipitation of hyaluronic acid, whereby the purified hyaluronic acid can be recovered. As the organic solvent, any conventional organic solvent such as ethanol, methanol, acetone, isopropyl alcohol, etc., preferably ethanol, may be used. After the precipitation, an organic solvent washing process may be additionally carried out for further removing impurities and making the drying process easy. Hyaluronic acid precipitated by an organic solvent is dried according to a conventional drying process known in the art, for example, nitrogen or air purging, freeze drying, vacuum drying, etc., to give the purified hyaluronic acid as white solid. The present inventors determined whether the finally obtained hyaluronic acid solid meets the standards of use as a medicine, according to the following method.
[51] As for the endotoxin, the hyaluronic acid sodium salt is dissolved to the concentration of lmg/ mi , and tested by using the LAL kit of Charles River Endosafe. The endotoxin content standard under the European Pharmacopoeia is 0.05 IU/mg or less. As for the protein, the hyaluronic acid sodium salt is dissolved to the concentration of lOmg/ m# , and quantified by Lo wry method. The protein content standard under the European Pharmacopoeia is 0.1% or less. Also, the protein of the sample in the intermediate step of purification is quantified by measuring the absorbance at 280nm. As for the nucleic acid, O.lOg of hyaluronic acid is dissolved to the final volume of 30.0
m#, and quantified by measuring the absorbance at 260nm. The nucleic acid content standard under the European Pharmacopoeia is 05 or less. As for the metallic impurities, 0.25g of hyaluronic acid is dissolved in 1 mi of nitric acid, heated, diluted to 10.0 m# with purified water, and quantified by the atomic absorption spectrometry II according to the European Pharmacopoeia (see Sodium Hyaluronate Test Method and Bacterial Endotoxins in the European Pharmacopoeia).
[52]
[53] L Mode for Invention J
[54] The present invention will be more specifically explained by the following examples and comparative examples. However, it should be understood that these examples are intended to illustrate the present invention, but not in any manner to limit the scope of the present invention.
[55]
[56] Example 1: Preparation of culture broth containing hyaluronic acid
[57] 1.1. Preparation of seed culture medium
[58] A medium having the final concentrations of 20g/L of glucose, 30g/L of yeast extract, 9g/L of sodium glutamate, 2g/L of sodium chloride, 2g/L of magnesium sulfate, and 2g/L of potassium phosphate dibasic was prepared. Only, glucose and magnesium sulfate were dissolved in another flask, sterilized, cooled, and mixed with the other components.
[59]
[60] 1.2. Seed culture 1
[61] To 50 m# of the medium prepared in Step 1.1 was inoculated 1 mi of Streptococcus zooepidemicus (KCTC 0075BP), and the mixture was incubated for about 24 h in a shaking incubator under the conditions of 35 0C and lOOrpm.
[62]
[63] 1.3. Seed culture 2
[64] To 950 m# of the medium prepared in Step 1.1 was inoculated 50 m# of the broth of seed culture 1 prepared in Step 1.2, and the mixture was incubated for about 24 h in a shaking incubator under the conditions of 35 0C and lOOrpm.
[65]
[66] 1.4. Preparation of main culture medium
[67] A medium having the final concentrations of 70g/L of glucose, 30g/L of yeast extract, 9g/L of sodium glutamate, 2g/L of sodium chloride, and 2g/L of magnesium sulfate was prepared. Glucose and magnesium sulfate were dissolved in another flask
and sterilized. The other components were sterilized in a 15L fermenter, cooled, and mixed with the components in the flask.
[68]
[69] 1.5. Main culture
[70] To a 15L fermenter including 9L of the medium prepared in Step 1.4 was inoculated
IL of the broth of seed culture 2, and the mixture was incubated under the conditions of 35 0C and 200rpm until the concentration of glucose is lowered to lg/L or less. The culture broth was maintained at pH 69 to 7.3, and IVVM of air flow during the incubation.
[71]
[72] Example 2: Purification of hyaluronic acid
[73] 2.1. Removal of cells
[74] To the hyaluronic acid-containing broth prepared in Example 1 was added the same volume of purified water to dilute the solution to have the concentration of hyaluronic acid within the range of 0.1-0.4%. 2% of diatomaceous earth with respect to the diluted solution was added, and the resulting solution was filtered through a depth filter to remove the cells and to obtain the hyaluronic acid-containing supernatant.
[75]
[76] 2.2. Ultrafiltration
[77] The cell-free hyaluronic acid-containing supernatant was concentrated to 1/2 volume by using a membrane whose molecular weight cut off is 30,000 Da. Ultrafiltration was carried out while constant volume was maintained by adding purified water, and stopped when conductivity of the hyaluronic acid-containing solution was 2mS/cm.
[78]
[79] 2.3. Adsorption
[80] 2% of charcoal and 1% of gamma alumina were added to the solution obtained from the ultrafiltration, and sodium chloride was added to the concentration of IM. The resulting mixture was stirred for about 5 h to adsorb such impurities as proteins, nucleic acids, endotoxins, etc., and filtered to remove the adsorbent and obtain a supernatant.
[81]
[82] 2.4. EDTA treatment
[83] To the supernatant after the adsorption was added EDTA to make the final concentration ImM, and the resulting mixture was stirred for 10 min.
[84]
[85] 2.5. Ethanol precipitation [86] To the hyaluronic acid-containing supernatant was added the same volume of 95% ethanol to precipitate hyaluronic acid. Thus obtained precipitate was recovered, washed with 80% ethanol five (5) times, and dried under nitrogen gas.
[87] [88] Comparative Example 1 [89] The same procedure as Example 2 was carried out to purify hyaluronic acid except that ultrafiltration was omitted.
[90] [91] Comparative Example 2 [92] The same procedure as Example 2 was carried out to purify hyaluronic acid except that adsoiption was omitted.
[93] [94] The following Table 1 compares the contents of impurities such as proteins, endotoxins, nucleic acids, etc. in the hyaluronic acid purified according to Example 2, Comparative Exanples 1 and 2 after dissolving the hyaluronic acid powder in water. As is confirmed by the results of Table 1, carrying out both ultrafiltration and adsorption is very effective for the removal of impurities.
[95] [96] Table 1
[97] [98] Comparative Example 3 [99] The ultrafiltration and adsoiption steps were carried out in the same manner as Example 2, but the ethanol precipitation and the subsequent steps were omitted.
[100] [101] Comparative Example 4 [102] Hyaluronic acid was purified according to the same procedure as Comparative Example 3 except that ultrafiltration and adsorption were carried out in the reversed order.
[103]
[104] The following Table 2 compares the contents of impurities such as proteins, endotoxins, nucleic acids, etc. in the hyaluronic acid purified according to Comparative Examples 3 and 4. As is confirmed by the results of Table 2, it is more effective for reducing the contents of impurities to carry out ultrafiltration first and adsorption later.
[105] [106] Table 2
[107] [108] The experimental results of Tables 1 and 2 show that the combination of ultrafiltration and adsorption is very effective for removing such impurities as proteins, endotoxins, nucleic acids, etc. from the hyaluronic acid-containing broth. Specifically, they show that the contents of impurities may be reduced to meet the standards of the European Pharmacopoeia only when ultrafiltration is carried out first, and adsorption later.
[109] [HO] Example 3: Effect for removing impurities depending on the kind and amount of adsorbent
[111] The cells were removed, and then ultrafiltration and adsorption were carried out according to the same procedure as Example 2, except that the kind and amount of adsorbent were changed as shown in the following Table 3. After removal of the adsorbent, the amounts of proteins, endotoxins and nucleic acids in the hyaluronic acid-containing supernatant were measured, as compared in Table 3.
[114] [115] The results of Table 3 shows that (i) charcoal is more effective than gamma alumina in removing such impurities as proteins, endotoxins, nucleic acids, etc.; (ii) 3% concentration of charcoal is more preferable than 05% concentration thereof; and (iii) it is more advantageous to use charcoal and gamma alumina together than to use only either of them.
[116] [117] Comparative Example 5: Effect for removing metallic impurities by EDTA treatment
[118] Hyaluronic acid was purified according to the same procedure as Example 2 except that EDTA treatment was not carried out. The following Table 4 compares the concentrations of metallic impurities in the purification product obtained with or without the EDTA treatment. The results of Table 4 show that the EDTA treatment is essential for treating metallic impurities.
[121] (Note) Unit: ppm [122] [123] L Industrial Applicability J [124] The purification method according to the present invention can be broadly used for purifying hyaluronic acid from the hyaluronic acid-containing broth obtained by the culture of microorganism. Also, the present invention makes it possible to omit the complicated organic solvent precipitation step in the purification process, whereby hyaluronic acid having a high purity can be obtained by a simple and economical method. Thus obtained hyaluronic acid has a purity that is appropriate as a medicine.
Claims
[I] L A method for purifying hyaluronic acid or salts thereof, which comprises the steps of
(a) removing cells from a hyaluronic acid-containing broth,
(b) ultrafiltering the cell-free broth,
(c) adding charcoal to the solution obtained in step (b) to adsorb impurities, and removing the adsorbent, and
(d) adding an organic solvent to the solution obtained in step (c) to precipitate hyaluronic acid, washing the precipitate with an organic solvent, and drying the precipitate.
[2] 2. The method of Claim 1 wherein the cells are removed by using diatomaceous earth.
[3] 3. The method of Claim 2 wherein diatomaceous earth is used in an amount of
05 to 5%.
[4] 4. The method of Claim 1 wherein the molecular weight cut off of the ultrafiltration membrane filter ranges from 5,000 to 300,000Da.
[5] 5. The method of Claim 1 wherein gamma alumina is further used with charcoal in the adsorption step (c).
[6] 6L The method of Claim 1 wherein charcoal is used in an amount of 05-5%, and gamma alumina is used in an amount of 0-3%.
[7] 7. A method for purifying hyaluronic acid or salts thereof, which comprises the step of removing metal ions.
[8] 8. The method of Claim 7 wherein a chelating agent is used for removing metal ions.
[9] 9. The method of Claim 8 wherein EDTA is used as chelating agent for removing metal ions.
[10] 10. The method of Claim 1, which further comprises the step of adding EDTA
[I I]
11. The method of Claim 10, which comprises the step of adding EDTA between the steps (c) and (d).
[12] 12. The method of Claim 10 or 11, wherein EDTA is added to a final concentration of 0.01-1OmM.
[13] 13. The method of Claim 1, wherein the organic solvent of step (d) is selected from ethanol, methanol, acetone and isopropyl alcohol.
[14] 14. The method of Claim 13, wherein the organic solvent is ethanol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0116319 | 2006-11-23 | ||
KR20060116319A KR101509139B1 (en) | 2006-11-23 | 2006-11-23 | Method for purifying hyaluronic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008062998A1 true WO2008062998A1 (en) | 2008-05-29 |
Family
ID=39429898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/005857 WO2008062998A1 (en) | 2006-11-23 | 2007-11-21 | Method for purifying hyaluronic acid |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101509139B1 (en) |
WO (1) | WO2008062998A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103936882A (en) * | 2013-01-21 | 2014-07-23 | 上海昊海生物科技股份有限公司 | Method for rapid preparation of sodium hyaluronate from sodium hyaluronate fermentation broth |
CN104059169A (en) * | 2014-06-11 | 2014-09-24 | 滨州安华生物工程有限公司 | Hyaluronic acid purification process |
ITMI20131654A1 (en) * | 2013-10-07 | 2015-04-08 | Rosa Mario De | PURIFICATION DOWNSTREAM OF HYALURONIC ACID FROM MICROBIAL COLORS |
CN105816414A (en) * | 2016-04-05 | 2016-08-03 | 广州市娇兰化妆品有限公司 | Yeast water and preparation method as well as application thereof to cosmetics |
CN106632727A (en) * | 2016-09-24 | 2017-05-10 | 合肥信达膜科技有限公司 | A hyaluronic acid extraction process |
IT201700081449A1 (en) * | 2017-07-18 | 2019-01-18 | Fidia Farm Spa | PURIFICATION PROCEDURE OF HYALURONIC ACID |
CN112851833A (en) * | 2021-02-04 | 2021-05-28 | 合肥博思科创医药科技有限公司 | Purification method for reducing protein content in sodium hyaluronate and derivatives thereof |
RU2765951C1 (en) * | 2021-05-14 | 2022-02-07 | Общество с ограниченной ответственностью "АВЕО" | Method of purifying hyaluronate from endotoxins |
CN115974940A (en) * | 2022-09-01 | 2023-04-18 | 华熙生物科技股份有限公司 | Membrane purification method of homogeneous hyaluronic acid oligosaccharide |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101132114B1 (en) * | 2009-09-15 | 2012-04-05 | 일동제약주식회사 | Method of molecular weight control of hyaluronic acid |
JP5758878B2 (en) * | 2010-03-17 | 2015-08-05 | 電気化学工業株式会社 | Purification method of hyaluronic acid |
WO2011114470A1 (en) * | 2010-03-17 | 2011-09-22 | 電気化学工業株式会社 | Hyaluronic acid purification method and production method |
KR101638662B1 (en) * | 2010-03-17 | 2016-07-11 | 덴카 주식회사 | Purification method for hyaluronic acid andor salts thereof |
CN114805636B (en) * | 2022-05-26 | 2023-08-04 | 宁夏华吉生物有限公司 | Method for preparing sodium hyaluronate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563051A (en) * | 1990-11-07 | 1996-10-08 | Fermentech Medical Limited | Production of hyaluronic acid |
US5591716A (en) * | 1993-11-19 | 1997-01-07 | New York University | Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins |
US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
US6537795B1 (en) * | 1994-05-26 | 2003-03-25 | Pharmacia Ab | Method and means for the production of hyaluronic acid |
US6610666B1 (en) * | 1999-11-08 | 2003-08-26 | Bio-Hyos Ab | Hyaluronan product and process for manufacturing thereof |
WO2004016771A1 (en) * | 2002-08-19 | 2004-02-26 | Kolon Ind. Inc. | Microorganism producing hyaluronic acid and purification method of hyaluronic acid |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1247175B (en) * | 1991-04-19 | 1994-12-12 | Fidia Spa | PROCEDURE FOR PURIFICATION OF HYALURONIC ACID AND FRACTION OF PURE HYALURONIC ACID FOR OPHTHALMIC USE. |
KR100312638B1 (en) * | 1994-09-09 | 2001-12-28 | 손 경 식 | Method for manufacturing high purity hyaluronic acid |
-
2006
- 2006-11-23 KR KR20060116319A patent/KR101509139B1/en active IP Right Grant
-
2007
- 2007-11-21 WO PCT/KR2007/005857 patent/WO2008062998A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563051A (en) * | 1990-11-07 | 1996-10-08 | Fermentech Medical Limited | Production of hyaluronic acid |
US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
US5591716A (en) * | 1993-11-19 | 1997-01-07 | New York University | Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins |
US6537795B1 (en) * | 1994-05-26 | 2003-03-25 | Pharmacia Ab | Method and means for the production of hyaluronic acid |
US6610666B1 (en) * | 1999-11-08 | 2003-08-26 | Bio-Hyos Ab | Hyaluronan product and process for manufacturing thereof |
WO2004016771A1 (en) * | 2002-08-19 | 2004-02-26 | Kolon Ind. Inc. | Microorganism producing hyaluronic acid and purification method of hyaluronic acid |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103936882A (en) * | 2013-01-21 | 2014-07-23 | 上海昊海生物科技股份有限公司 | Method for rapid preparation of sodium hyaluronate from sodium hyaluronate fermentation broth |
ITMI20131654A1 (en) * | 2013-10-07 | 2015-04-08 | Rosa Mario De | PURIFICATION DOWNSTREAM OF HYALURONIC ACID FROM MICROBIAL COLORS |
CN104059169A (en) * | 2014-06-11 | 2014-09-24 | 滨州安华生物工程有限公司 | Hyaluronic acid purification process |
CN105816414A (en) * | 2016-04-05 | 2016-08-03 | 广州市娇兰化妆品有限公司 | Yeast water and preparation method as well as application thereof to cosmetics |
CN105816414B (en) * | 2016-04-05 | 2018-07-31 | 广州市娇兰化妆品有限公司 | A kind of yeast water and preparation method thereof and the application in cosmetics |
CN106632727A (en) * | 2016-09-24 | 2017-05-10 | 合肥信达膜科技有限公司 | A hyaluronic acid extraction process |
IT201700081449A1 (en) * | 2017-07-18 | 2019-01-18 | Fidia Farm Spa | PURIFICATION PROCEDURE OF HYALURONIC ACID |
WO2019016699A1 (en) * | 2017-07-18 | 2019-01-24 | Fidia Farmaceutici S.P.A. | Process for the purification of hyaluronic acid |
CN110612153A (en) * | 2017-07-18 | 2019-12-24 | 费迪亚医药股份公司 | Method for purifying hyaluronic acid |
EA039639B1 (en) * | 2017-07-18 | 2022-02-21 | Фидия Фармачеутичи С.П.А. | Process for the extraction and purification of hyaluronic acid |
CN110612153B (en) * | 2017-07-18 | 2022-07-12 | 费迪亚医药股份公司 | Method for purifying hyaluronic acid |
CN112851833A (en) * | 2021-02-04 | 2021-05-28 | 合肥博思科创医药科技有限公司 | Purification method for reducing protein content in sodium hyaluronate and derivatives thereof |
CN112851833B (en) * | 2021-02-04 | 2022-06-28 | 合肥博思科创医药科技有限公司 | Purification method for reducing protein content in sodium hyaluronate and derivatives thereof |
RU2765951C1 (en) * | 2021-05-14 | 2022-02-07 | Общество с ограниченной ответственностью "АВЕО" | Method of purifying hyaluronate from endotoxins |
CN115974940A (en) * | 2022-09-01 | 2023-04-18 | 华熙生物科技股份有限公司 | Membrane purification method of homogeneous hyaluronic acid oligosaccharide |
Also Published As
Publication number | Publication date |
---|---|
KR101509139B1 (en) | 2015-04-08 |
KR20080046821A (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008062998A1 (en) | Method for purifying hyaluronic acid | |
JP7105888B2 (en) | Low-molecular-weight hyaluronic acid or its salt and its preparation method | |
JPH09324001A (en) | Purification method for sodium hyaluronate | |
KR19980080116A (en) | Purification Method of Sodium Hyaluronate | |
ITMI20121184A1 (en) | PROCESS FOR INDUSTRIAL PRODUCTION OF SODIUM IALURONATE (HANA) HIGHLY PURIFIED WITH CONTROLLED MOLECULAR WEIGHT | |
JP2020507666A (en) | Decomposition method of polysaccharide using ozone | |
JP5750442B2 (en) | Low molecular weight hyaluronic acid production method | |
EP0811690B1 (en) | Water-insoluble glucan purification method | |
KR101639105B1 (en) | Hyaluronic acid purification method and production method | |
CN108456262A (en) | A kind of preparation process of high purity heparin sodium | |
JP2004018840A (en) | N-acetylheparosan fraction and method for producing the same | |
CN110863024A (en) | Method for preparing micromolecular hyaluronic acid by utilizing squid eyes | |
KR101627014B1 (en) | Hyaluronic acid purification method | |
KR0149793B1 (en) | Purification method of high molecular hydraulic acid | |
KR100236766B1 (en) | Purification method for hyaluronic acid and its salts | |
KR100312638B1 (en) | Method for manufacturing high purity hyaluronic acid | |
KR100829086B1 (en) | Purification method of hyaluronic acid or salt thereof | |
JPH02245193A (en) | Production of alkali salt of hyaluronic acid having low polymerization degree | |
JPH01313503A (en) | Purification of hyaluronic acid | |
Kanala et al. | Microbial production of high purity hyaluronic acid from Streptococcus zooepidemicus | |
EP1941889A1 (en) | Method for producing sulphated glycosaminoglycans from a biological tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07834163 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07834163 Country of ref document: EP Kind code of ref document: A1 |